Chicago’s Healthcare Tech Scene Gains Momentum as Tempus Lifts Guidance and Funding Rebounds
Chicago’s healthcare technology sector is entering mid-2026 with renewed momentum, powered by a flagship public company raising its outlook, an anchor incubator widening its reach, and a national funding climate that has turned friendlier after several uneven years. Together, those forces are reinforcing the city’s claim as one of the country’s serious centers for digital health, built on a combination of clinical institutions, data expertise, and a maturing startup base.
Tempus Anchors The Comeback
The clearest signal is coming from Tempus AI, the Chicago-headquartered precision-medicine company. In its first-quarter report, Tempus posted revenue of $348.1 million, up 36.1% year over year, and raised its full-year 2026 guidance to between $1.59 billion and $1.60 billion with adjusted EBITDA of roughly $65 million. The company ended March with $643.8 million in cash and marketable securities, and it hosted an investor day at its Chicago headquarters on May 29.
Founder and chief executive Eric Lefkofsky said the results reflected “accelerating demand” for the company’s AI-driven diagnostic platform. The growth has been paired with clinical and commercial milestones, including a multi-year strategic collaboration with Merck to accelerate biomarker discovery, and a study with Medtronic showing that AI-driven electronic health record notifications increased life-saving heart valve procedures. The U.S. Food and Drug Administration also granted approval for a tumor-only indication on the company’s xT CDx sequencing platform, expanding the patients its tests can reach.
A profitable, scaling anchor company matters for an ecosystem because it keeps talent, capital, and intellectual property circulating locally rather than migrating to the coasts.
MATTER And The Incubator Engine
If Tempus is the headline, MATTER is the connective tissue. The incubator, based at the Merchandise Mart, has spent more than a decade pairing entrepreneurs with the executives, investors, and health systems that can turn a prototype into a product. It now operates Paratus, a BARDA Accelerator Network hub for digital health, positioning Chicago founders close to federal preparedness funding and partnerships.
MATTER has also leaned into equity-focused growth. Its Health Equity Innovation accelerator, run jointly with YWCA Metropolitan Chicago, supports entrepreneurs building solutions that advance health equity through an eight-week, cohort-based program. That emphasis fits a city where health disparities across neighborhoods are a persistent civic concern, giving the local startup scene a community dimension beyond pure commercial ambition.
A Rebound In Capital
The local momentum is riding a national recovery in digital-health investment. According to Rock Health, digital health startups raised $4 billion across 110 deals in the first quarter of 2026, a $1 billion increase over the same period a year earlier and the strongest first quarter since the pandemic peak. The average deal size reached $36.7 million, the highest since late 2021, a sign that investors are writing bigger checks for fewer, more proven companies.
That selectivity favors markets with established players and infrastructure, which works to Chicago’s advantage. The city’s hospital innovation teams at Northwestern, Rush, and the University of Chicago routinely run pilots that validate young companies, while local and corporate venture arms, including the investment unit tied to Blue Cross Blue Shield, keep capital flowing into homegrown startups.
Why It Matters For Chicago
The practical payoff shows up in jobs and retained expertise. Scaling health-tech firms hire across clinical, data-engineering, artificial-intelligence, and operations roles, the kind of durable, well-paying positions that anchor a knowledge economy. When a company like Tempus expands from Chicago rather than relocating, the benefit compounds: graduates from local universities find reasons to stay, vendors and service firms gain customers, and the city builds a reputation that draws the next wave of founders.
There is also a civic argument. Tools developed in Chicago, from diagnostic platforms to care-coordination software, increasingly reach patients far beyond the metro area, extending the city’s influence in how medicine is delivered nationally.
The Caveats
The progress is real but uneven. Rock Health has described the broader market as a story of haves and have-nots, with funding concentrating in a handful of larger, AI-native platforms while smaller startups struggle to raise. Tempus itself illustrates the tension between growth and profitability; the company reported a net loss of $125.9 million in the first quarter, and management has signaled it will pace expansion of newer tests in line with reimbursement progress to avoid burning cash too quickly.
Policy uncertainty adds another variable, from shifting federal health priorities to a still-narrow IPO window that limits exits. For now, though, the direction in Chicago is upward, and the combination of an anchor company, a dependable incubator, and returning capital gives the city’s health-tech scene a foundation that looks built to last.



